AMGN Key Statistics, Chart & Performance
The current stock price of AMGN is 323.349 USD. In the past month the price increased by 2.57%. In the past year, price increased by 19.64%.
AMGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.15 | 386.65B | ||
| GILD | GILEAD SCIENCES INC | 14.95 | 151.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.45 | 116.50B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.75 | 79.23B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 723.39 | 48.74B | ||
| INSM | INSMED INC | N/A | 35.15B | ||
| NTRA | NATERA INC | N/A | 32.28B | ||
| BIIB | BIOGEN INC | 10.92 | 26.82B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.17B | ||
| INCY | INCYTE CORP | 16.61 | 20.94B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.17 | 20.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.37B |
Related stock screener links
About AMGN
Company Profile
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 28,000 full-time employees. The company discovers, develops, manufactures and delivers medicines for the toughest diseases. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. The company operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. The company markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. The company markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. The company markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Company Info
AMGEN INC
One Amgen Center Drive
Thousand Oaks CALIFORNIA 91320 US
CEO: Robert A. Bradway
Employees: 28000
Phone: 18054471000
AMGEN INC / AMGN FAQ
Can you describe the business of AMGEN INC?
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 28,000 full-time employees. The company discovers, develops, manufactures and delivers medicines for the toughest diseases. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. The company operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. The company markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. The company markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. The company markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
What is the stock price of AMGEN INC today?
The current stock price of AMGN is 323.349 USD. The price decreased by -0.67% in the last trading session.
Does AMGN stock pay dividends?
AMGEN INC (AMGN) has a dividend yield of 3.05%. The yearly dividend amount is currently 9.01.
What is the ChartMill technical and fundamental rating of AMGN stock?
AMGN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Can you provide the upcoming dividend date for AMGEN INC?
The next ex-dividend date for AMGEN INC (AMGN) is February 13, 2026.
Can you provide the market cap for AMGEN INC?
AMGEN INC (AMGN) has a market capitalization of 174.12B USD. This makes AMGN a Large Cap stock.
Can you provide the upcoming earnings date for AMGEN INC?
AMGEN INC (AMGN) will report earnings on 2026-02-03, after the market close.
AMGN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to AMGN. When comparing the yearly performance of all stocks, AMGN is one of the better performing stocks in the market, outperforming 74.94% of all stocks.
AMGN Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to AMGN. AMGN scores excellent on profitability, but there are concerns on its financial health.
AMGN Financial Highlights
Over the last trailing twelve months AMGN reported a non-GAAP Earnings per Share(EPS) of 21.87. The EPS increased by 13.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 19.47% | ||
| ROA | 7.77% | ||
| ROE | 72.82% | ||
| Debt/Equity | 5.45 |
AMGN Forecast & Estimates
41 analysts have analysed AMGN and the average price target is 334.67 USD. This implies a price increase of 3.5% is expected in the next year compared to the current price of 323.349.
For the next year, analysts expect an EPS growth of 9.46% and a revenue growth 9.43% for AMGN